IL‐33‐driven expansion of ILC2s also appears relevant for effective anti‐tumour responses in hepatocellular carcinoma (HCC), where patients with elevated IL‐33 levels and favourable ILC2 to ILC1 ratios exhibit improved clinical outcomes [115]. Here, IL33 is linked to neoplasm.